All In Biotech

Drug Trial Radar · NCT06198556

Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects

A Single Center, Single Arm, Open, Fixed Sequence Study on the Pharmacokinetic Effects of Rifampicin on Oral Administration of HRS-1167 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jan 14, 2024

Primary completion

Feb 5, 2024

Study completion Feb 5, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets. The secondary objective of the study is to evaluate the safety of HRS-1167 alone and when co-administered with rifampicin.

Conditions

  • Advanced Solid Tumor

Interventions

  • HRS-1167 tablets; rifampicinDrug

    HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics parameters of HRS1167: CmaxTime frame: Based on pre-dose, 0-72 hours post-dose sampling times
  2. Pharmacokinetics parameters of HRS1167: AUC0-tTime frame: Based on pre-dose, 0-72 hours post-dose sampling times
  3. Pharmacokinetics parameters of HRS1167: AUC0-infTime frame: Based on pre-dose, 0-72 hours post-dose sampling times

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.